Health Condition 1: F422- Mixed obsessional thoughts and acts
Conditions
Interventions
Intervention1: Celecoxib Drug: Celecoxib is a COX-2 Inhibitor that acts as an antiinflammatory agent. It will be given orally along with Fluoxetine in OCD patients at a dose of 200mg BD (400mg/day) fo
Sponsors
King George Medical University
Eligibility
Inclusion criteria
Inclusion criteria: Informed consent from the patient Diagnosed with OCD (ICD-10 DCR) Symptomatic (Y-BOCS Score more than or equal to 21) Drug naive (Drug free period for at least 12 weeks)
Exclusion criteria
Exclusion criteria: Any other psychiatric comorbidity(Except nicotine dependence) Any medical condition requiring priority management or where use of COX-2 inhibitors is contraindicated Patient receiving a course of any immunosuppressive therapy or NSAID in adequate dose for consecutive 5 days or more in the past 8 weeks. Established non-response to Fluoxetine (Adequate dose for adequate duration) Intellectual disability (assessed clinically), Pregnancy and breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To study the severity of Obsessive Compulsive Disorder with Celecoxib add-on therapy to fluoxetine Timepoint: Baseline, 2 weeks, 4 weeks, 8 weeks, 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| To study the cognition patients of Obsessive Compulsive Disorder with Celecoxib add-on therapy to fluoxetine To study the associated anxiety and depressive symptoms in patients of Obsessive Compulsive Disorder with Celecoxib add-on therapy to fluoxetine To study the quality of life in patients of Obsessive Compulsive Disorder with Celecoxib add-on therapy to fluoxetine To study the functioning in patients of Obsessive Compulsive Disorder with Celecoxib add-on therapy to fluoxetine Timepoint: Baseline, 2 weeks, 4 weeks, 8 weeks, 12 weeks | — |
Countries
India
Contacts
Public ContactDr Shivangini Singh
Department of Psychaitry KGMU
Outcome results
None listed